To date, there have been several clinical trials in HNSCC utilizing TGF-β targeting agents either in monotherapy or in combination with other cytotoxic regimens or immunotherapies (Table 1). This evidence concerns the gene TGFB1 and head and neck squamous cell carcinoma.